Uncategorized
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
AstraZeneca remains “very much on track” to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said during the company’s Q2 earnings presentation on Monday. Read More